Related Experiment Video

Updated: May 28, 2026

Chromosome Preparation From Cultured Cells
07:42

Chromosome Preparation From Cultured Cells

Published on: January 28, 2014

The 5q- syndrome: biology and treatment

Eric Padron1, Rami Komrokji, Alan F List

  • 1H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA. eric.padron@moffitt.org

Current Treatment Options in Oncology
|October 4, 2011
PubMed
Abstract

Insights

Lenalidomide effectively treats symptomatic anemia in 5q- syndrome, a type of myelodysplastic syndrome (MDS). This treatment reduces transfusion needs and iron overload, improving patient outcomes.

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • 5q- syndrome is a myelodysplastic syndrome (MDS) with characteristic anemia and slow progression.
  • Advances in understanding molecular pathogenesis reveal targets for lenalidomide therapy.
  • Effective management of lower-risk MDS, including 5q- syndrome, focuses on cytopenias.

Purpose of the Study:

  • To review the current understanding of 5q- syndrome biology.
  • To discuss the efficacy and actions of lenalidomide in treating 5q- syndrome.
  • To outline clinical management strategies for 5q- syndrome.

Main Methods:

  • Literature review of 5q- syndrome pathogenesis and lenalidomide efficacy.
  • Analysis of clinical data regarding lenalidomide treatment outcomes.
  • Synthesis of current knowledge on biological mechanisms and treatment strategies.

Main Results:

  • Lenalidomide is the preferred treatment for symptomatic anemia in 5q- syndrome.
  • The majority of patients experience reduced transfusion dependence and iron overload.
  • Understanding molecular targets explains lenalidomide's selective efficacy.

Conclusions:

  • Lenalidomide is a crucial therapeutic option for managing symptomatic anemia in 5q- syndrome.
  • Treatment should prioritize ameliorating refractory cytopenias.
  • Further research into 5q- syndrome biology and lenalidomide mechanisms is warranted.

More Related Videos

A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations08:22

A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations

Published on: December 1, 2017

Array Comparative Genomic Hybridization (Array CGH) for Detection of Genomic Copy Number Variants09:16

Array Comparative Genomic Hybridization (Array CGH) for Detection of Genomic Copy Number Variants

Published on: February 21, 2015

Related Concept Videos

Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
Sex-linked Disorders01:43

Sex-linked Disorders

Like autosomes, sex chromosomes contain a variety of genes necessary for normal body function. When a mutation in one of these genes results in biological deficits, the disorder is considered sex-linked.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Sex Linked Disorders01:43

Sex Linked Disorders

Like autosomes, sex chromosomes contain a variety of genes necessary for normal body function. When a mutation in one of these genes results in biological deficits, the disorder is considered sex-linked.
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...